Iambic goes public with $150M IPO to accelerate clinical development of oncology pipeline | #biotech #biotechsky #AI www.fiercebiotech.com/biotech/iamb...
@markfortner.bsky.social
@markfortner.bsky.socialIambic goes public with $150M IPO to accelerate clinical development of oncology pipeline | #biotech #biotechsky #AI www.fiercebiotech.com/biotech/iamb...
@markfortner.bsky.socialArrowhead's brain-targeting drug lowers Alzheimer's tau protein in early study | #biotechsky #biotech #Alzheimers
@markfortner.bsky.social@markfortner.bsky.social@markfortner.bsky.socialBiotech start-ups turn to reverse mergers to fast-track listings | #biotech #biotechsky www.ft.com/content/987c...
@markfortner.bsky.socialPfizer pens $500M Enodia pact to join in emerging protein degrader field | #TPD #biotech #pharma #biotechsky
@markfortner.bsky.socialNurix drops one BTK degrader as momentum builds behind Roche-partnered option | #biotech #pharma #TPD #chemsky #biotechsky
@markfortner.bsky.socialCaribou Biosciences, #biotech founded by Jennifer Doudna, is shutting down | #biotechsky
@markfortner.bsky.social@markfortner.bsky.socialGenentech pays Alector $100M for preclinical Parkinson’s prospect | #biotechsky #biotech #pharma
@markfortner.bsky.socialIntroducing Fierce Biotech's 2026 Fierce 15 | #biotechsky #biotech
@markfortner.bsky.socialFor years, pancreatic cancer was untargettable. RevMed just flipped the script on active RAS. #biotechsky #biotech #cancer #PancreaticCancer
Full breakdown on the Target Space podcast: firebasestorage.googleapis.com/v0/b/viridia....
@markfortner.bsky.social"We're so close to the tech companies": Genentech CEO talks Fierce through vision for the future | #biotech #biotechsky #pharma